AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21663811 — intervention group
Group type: EXPERIMENTAL
Intervention: Airtraq (A)
Number of subjects: 62
Study 21663811 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope (G)
Number of subjects: 62
Study 21663811 — intervention group
Group type: COMPARATOR
Intervention: Macintosh (M)
Number of subjects: 62
Study 19801025 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus plus bivalirudin infusion during and after PCI (4 hours, n = 88)
Number of subjects: 178
Study 19801025 — intervention group
Group type: COMPARATOR
Intervention: Bolus plus bivalirudin infusion during PCI (n = 90)
Number of subjects: 178
Study 16788335 — intervention group
Group type: EXPERIMENTAL
Intervention: Early access to physical therapy treatment within 2 days (n=32)
Number of subjects: 60
Study 16788335 — intervention group
Group type: COMPARATOR
Intervention: Control group with a 4-week waiting list (n=28)
Number of subjects: 60
Study 15660594 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretch-release relaxation training
Number of subjects: 65
Study 15660594 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive relaxation training
Number of subjects: 65
Study 15660594 — intervention group
Group type: COMPARATOR
Intervention: Control group (test control)
Number of subjects: 65
Study 10875212 — intervention group
Group type: COMPARATOR
Intervention: Carotid stenting
Number of subjects: 0
Study 10875212 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy
Number of subjects: 0
Study 9594558 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP)
Number of subjects: 27
Study 9594558 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelin-1,2 (ET-1,2)
Number of subjects: 27
Study 9594558 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropeptide Y (NPY)
Number of subjects: 27
Study 8322577 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-viscosity cement
Number of subjects: 267
Study 8322577 — intervention group
Group type: COMPARATOR
Intervention: High-viscosity cement
Number of subjects: 267
Study 3793001 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (20 mg i.v.)
Number of subjects: 33
Study 3793001 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone (10 mg i.v.)
Number of subjects: 33
Study 3793001 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 31599603 — intervention group
Group type: EXPERIMENTAL
Intervention: CM-reinforced exercise intervention
Number of subjects: 120
Study 31599603 — intervention group
Group type: EXPERIMENTAL
Intervention: CM for completing exercise goals
Number of subjects: 120
Study 31599603 — intervention group
Group type: COMPARATOR
Intervention: CM for completing general nonexercise goals
Number of subjects: 120
Study 31151228 — intervention group
Group type: EXPERIMENTAL
Intervention: early time-restricted feeding (eTRF)
Number of subjects: 11
Study 28952284 — intervention group
Group type: EXPERIMENTAL
Intervention: Role playing
Number of subjects: 314
Study 28952284 — intervention group
Group type: COMPARATOR
Intervention: Lecture (Control)
Number of subjects: 314
Study 26923352 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid-sparing immunosuppressive regimens
Number of subjects: 112
Study 26923352 — intervention group
Group type: EXPERIMENTAL
Intervention: JCPyV positive donor IgG antibodies
Number of subjects: 112
Study 26923352 — intervention group
Group type: EXPERIMENTAL
Intervention: JCPyV positive
Number of subjects: 112
Study 26923352 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative JCPyV donor
Number of subjects: 112
Study 24433609 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing based intervention (n=15)
Number of subjects: 30
Study 24433609 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=15)
Number of subjects: 30
Study 21414035 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% diclofenac in 2.5% hyaluronic acid gel for 3 months
Number of subjects: 418
Study 21414035 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% diclofenac in 2.5% hyaluronic acid gel for 6 months
Number of subjects: 418
Study 21414035 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% diclofenac in 2.5% hyaluronic acid gel for 3 months and 6 months
Number of subjects: 418
Study 19996425 — intervention group
Group type: EXPERIMENTAL
Intervention: artesunate‐mefloquine (AMQ)
Number of subjects: 342
Study 19996425 — intervention group
Group type: COMPARATOR
Intervention: mefloquine (MQ)
Number of subjects: 342
Study 17451613 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glycaemic-index (GI) breakfast
Number of subjects: 2
Study 17451613 — intervention group
Group type: COMPARATOR
Intervention: High-glycaemic-index (GI) breakfast
Number of subjects: 2
Study 15105027 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein liquid nutritional supplement (Boost HP)
Number of subjects: 46
Study 15105027 — intervention group
Group type: COMPARATOR
Intervention: Standard liquid nutritional supplement (Ensure)
Number of subjects: 46
Study 11253315 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimanual in‐phase and antiphase tapping, clapping, galloping, galloping while clapping, crawling
Number of subjects: 15
Study 11253315 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural limb frequencies
Number of subjects: 15
Study 11253315 — intervention group
Group type: EXPERIMENTAL
Intervention: Single limb timing consistency
Number of subjects: 15
Study 9589230 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (6 g daily for 2 months)
Number of subjects: 12
Study 9589230 — intervention group
Group type: COMPARATOR
Intervention: Sunflower oil (6 g daily for 2 months)
Number of subjects: 12
Study 7990660 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-fed infants
Number of subjects: 35
Study 7990660 — intervention group
Group type: COMPARATOR
Intervention: Formula-fed infants
Number of subjects: 35
Study 2660451 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCG 115 BS (5 mg)
Number of subjects: 16
Study 2660451 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCG 115 BS (10 mg)
Number of subjects: 16
Study 2660451 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCG 115 BS (chronic treatment: 2 x 5 or 2 x 10 mg/d)
Number of subjects: 16
Study 2660451 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 30329038 — intervention group
Group type: EXPERIMENTAL
Intervention: Maribavir 400 mg twice daily
Number of subjects: 120
Study 30329038 — intervention group
Group type: EXPERIMENTAL
Intervention: Maribavir 800 mg twice daily
Number of subjects: 120
Study 30329038 — intervention group
Group type: EXPERIMENTAL
Intervention: Maribavir 1200 mg twice daily
Number of subjects: 120
Study 30329038 — intervention group
Group type: EXPERIMENTAL
Intervention: Maribavir (all doses combined)
Number of subjects: 120
Study 30329038 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 120
Study 30329038 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 120
Study 28474460 — intervention group
Group type: EXPERIMENTAL
Intervention: OXN PR (oxycodone-naloxone prolonged-release) at a mean daily dose of 130.7 mg (range 120-180 mg)
Number of subjects: 0
Study 28474460 — intervention group
Group type: EXPERIMENTAL
Intervention: OXN PR (oxycodone-naloxone prolonged-release)
Number of subjects: 0
Study 26342136 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention program (12 sessions over 6 months)
Number of subjects: 36
Study 24077372 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training group (19 boys, 22 girls)
Number of subjects: 125
Study 24077372 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training group (21 boys, 24 girls)
Number of subjects: 125
Study 24077372 — intervention group
Group type: COMPARATOR
Intervention: Control group (18 boys, 21 girls)
Number of subjects: 125
Study 21231888 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline buccoadhesive tablets
Number of subjects: 0
Study 21231888 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline buccoadhesive tablets with high-viscosity hydroxypropylmethyl cellulose (HPMC-K4M)
Number of subjects: 0
Study 21231888 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline buccoadhesive tablets with sodium carboxymethyl cellulose (NaCMC) and HPMC-E5LV
Number of subjects: 0
Study 21231888 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline buccoadhesive tablets with HPMC-E5LV
Number of subjects: 0
Study 19728577 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthodontic treatment (fixed appliance treatment)
Number of subjects: 183
Study 19728577 — intervention group
Group type: COMPARATOR
Intervention: Class II group (untreated)
Number of subjects: 183
Study 19728577 — intervention group
Group type: COMPARATOR
Intervention: Normal group (normal occlusion)
Number of subjects: 183
Study 17760537 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic scaler with carbon tips (VS)
Number of subjects: 14
Study 17760537 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic scaler with plastic tips (PS)
Number of subjects: 14
Study 17760537 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonic scaler with metallic tips (ES)
Number of subjects: 14
Study 17760537 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic scalers (VS, PS, ES)
Number of subjects: 14
Study 15050696 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐1alpha (-889C/T) polymorphism in PD patients
Number of subjects: 176
Study 15050696 — intervention group
Group type: COMPARATOR
Intervention: IL‐1alpha (-889C/T) polymorphism in control individuals
Number of subjects: 176
Study 15061246 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine 600 mg/day
Number of subjects: 0
Study 15061246 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol 20 mg/day
Number of subjects: 0
Study 10933062 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirapazamine (TPZ) administration
Number of subjects: 13
Study 8569225 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin for 4 weeks
Number of subjects: 0
Study 8569225 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin for 14 days
Number of subjects: 0
Study 8569225 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin between 8 and 12 weeks of rHuEpo therapy
Number of subjects: 0
Study 8569225 — intervention group
Group type: COMPARATOR
Intervention: Both groups of patients
Number of subjects: 0
Study 8569225 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin administration
Number of subjects: 0
Study 2037667 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal bivalent live attenuated influenza vaccine
Number of subjects: 102
Study 2037667 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral trivalent inactivated subvirion vaccine
Number of subjects: 102
Study 2037667 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 102
Study 2037667 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 6909025 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol 5 mg/day + 1% adrenaline eye drops
Number of subjects: 0
Study 6909025 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol 20 mg/day + 1% adrenaline eye drops
Number of subjects: 0
Study 6909025 — intervention group
Group type: COMPARATOR
Intervention: Timolol 5 mg/day + placebo eye drops
Number of subjects: 0
Study 6909025 — intervention group
Group type: COMPARATOR
Intervention: Timolol 20 mg/day + placebo eye drops
Number of subjects: 0
Study 31571150 — intervention group
Group type: EXPERIMENTAL
Intervention: Halibut maki roll with newly harvested Greenlandic seaweed salad
Number of subjects: 9
Study 31571150 — intervention group
Group type: COMPARATOR
Intervention: Halibut maki roll with no seaweed salad
Number of subjects: 9
Study 31571150 — intervention group
Group type: EXPERIMENTAL
Intervention: Halibut maki roll with Japanese seaweed salad
Number of subjects: 9
Study 31530354 — intervention group
Group type: COMPARATOR
Intervention: 2006 WHO growth standard (W-group)
Number of subjects: 15019
Study 31530354 — intervention group
Group type: EXPERIMENTAL
Intervention: 2005 Shanghai growth standard (S-group)
Number of subjects: 15019
Study 29463288 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine treatment administered through the local health system.
Number of subjects: 0
Study 29463288 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in the abstract).
Number of subjects: 0
Study 26739816 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent high-intensity exercise (IHE)
Number of subjects: 12
Study 26739816 — intervention group
Group type: COMPARATOR
Intervention: Continuous moderate intensity exercise (CONT)
Number of subjects: 12
Study 24953218 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% levobupivacaine
Number of subjects: 20
Study 24953218 — intervention group
Group type: COMPARATOR
Intervention: 0.5% racemic bupivacaine
Number of subjects: 20
Study 22451450 — intervention group
Group type: EXPERIMENTAL
Intervention: Azosemide
Number of subjects: 320
Study 22451450 — intervention group
Group type: COMPARATOR
Intervention: Furosemide
Number of subjects: 320
Study 20399288 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg every 6 months for 24 months
Number of subjects: 332
Study 20399288 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 332
Study 18083404 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with fluorouracil and folinic acid (n=1622)
Number of subjects: 3239
Study 18083404 — intervention group
Group type: COMPARATOR
Intervention: Observation (n=1617)
Number of subjects: 3239
Study 16139122 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 300 mg loading dose before PCI and 75 mg daily for one year afterward
Number of subjects: 2116
Study 16139122 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2116
Study 16139122 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 2116
Study 12153125 — intervention group
Group type: EXPERIMENTAL
Intervention: Smiling in photographs
Number of subjects: 496
Study 12153125 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative social status
Number of subjects: 496
Study 10456461 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmin-alpha2-antiplasmin complex (PAP) levels in patients with AF
Number of subjects: 586
Study 10456461 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk patients classified by risk stratification criteria
Number of subjects: 586
Study 10456461 — intervention group
Group type: COMPARATOR
Intervention: PAP levels in patients receiving warfarin
Number of subjects: 586
Study 8526244 — intervention group
Group type: EXPERIMENTAL
Intervention: d-alpha-tocopherol
Number of subjects: 73
Study 8526244 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 31687396 — intervention group
Group type: EXPERIMENTAL
Intervention: Lycopene
Number of subjects: 0
Study 31687396 — intervention group
Group type: COMPARATOR
Intervention: Pyrene
Number of subjects: 0
Study 27791253 — intervention group
Group type: EXPERIMENTAL
Intervention: HPG/PG/PL
Number of subjects: 210
Study 27791253 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 210
Study 26320082 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-percutaneous nephrolithotomy (mini-PCNL)
Number of subjects: 70
Study 26320082 — intervention group
Group type: COMPARATOR
Intervention: Retrograde intrarenal surgery (RIRS)
Number of subjects: 70
Study 26320082 — intervention group
Group type: COMPARATOR
Intervention: RIRS
Number of subjects: 70
Study 26320082 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-PCNL
Number of subjects: 70
Study 26320082 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study 23848034 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (Propofol‐allergy group)
Number of subjects: 140
Study 23848034 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane (Sevoflurane‐allergy group)
Number of subjects: 140
Study 23848034 — intervention group
Group type: COMPARATOR
Intervention: Propofol (Propofol‐non‐allergy group)
Number of subjects: 140
Study 23848034 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane (Sevoflurane‐non‐allergy group)
Number of subjects: 140
Study 21757914 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebamipide 300 mg daily for 7 weeks
Number of subjects: 132
Study 21757914 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg daily for 7 weeks
Number of subjects: 132
Study 19856194 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant stanol esters
Number of subjects: 2
Study 17012694 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with mild mental retardation
Number of subjects: 150
Study 17012694 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with moderate mental retardation
Number of subjects: 150
Study 17012694 — intervention group
Group type: COMPARATOR
Intervention: Comparison subjects without mental retardation
Number of subjects: 150
Study 17012694 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with mental retardation (mild and moderate)
Number of subjects: 150
Study 17012694 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with mental retardation
Number of subjects: 150
Study 15139576 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustable dosing of budesonide/formoterol (80/4.5 or 160/4.5 microg), 2 inhalations b.i.d.
Number of subjects: 1539
Study 15139576 — intervention group
Group type: COMPARATOR
Intervention: Fixed dosing of budesonide/formoterol (80/4.5 or 160/4.5 microg), 2 inhalations b.i.d.
Number of subjects: 1539
Study 10796741 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate, bolus 30mg/kg over 15 minutes with a maintenance infusion of 5.4 mg/kg per hour for 23 hours.
Number of subjects: 0
Study 10796741 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate, extended maintenance dose from 24 to 48 hours.
Number of subjects: 0
Study 10796741 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate, modified regimen.
Number of subjects: 0
Study 10796741 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate, therapy for whiplash injuries.
Number of subjects: 0
Study 9071954 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium diet (20 mmol sodium daily)
Number of subjects: 59
Study 9071954 — intervention group
Group type: COMPARATOR
Intervention: Normal diet
Number of subjects: 59
Study 8312208 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (1g single dose)
Number of subjects: 183
Study 3707794 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% and 2.5% isoflurane in oxygen
Number of subjects: 2
Study 3707794 — intervention group
Group type: COMPARATOR
Intervention: 0.75% and 1.75% isoflurane plus 67% nitrous oxide in oxygen
Number of subjects: 2
Study 3707794 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide group
Number of subjects: 2
Study 3707794 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 2
Study 30545921 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (440 mg/m2 days 1-5) / Etoposide (100 mg/m2 days 1-5) during part 2 of consolidation and delayed intensification
Number of subjects: 100
Study 30545921 — intervention group
Group type: COMPARATOR
Intervention: Modified Berlin-Frankfurt-Münster regimen (control arm)
Number of subjects: 100
Study 30545921 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 100
Study 28427550 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-made spacer (HmS)
Number of subjects: 63
Study 28427550 — intervention group
Group type: COMPARATOR
Intervention: Valved commercial spacer (VCS)
Number of subjects: 63
Study 28427550 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (HmS and VCS)
Number of subjects: 63
Study 26218256 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight glycemic control (target blood glucose, 4-7 mmol/L) with insulin titration based on blood glucose values and rate of change.
Number of subjects: 92
Study 23706063 — intervention group
Group type: EXPERIMENTAL
Intervention: Triticum monococcum (Tm) - 2.5 grams
Number of subjects: 12
Study 23706063 — intervention group
Group type: COMPARATOR
Intervention: Rice (as reference atoxic protein) - 2.5 grams
Number of subjects: 12
Study 23706063 — intervention group
Group type: COMPARATOR
Intervention: Amygluten (as reference toxic protein) - 2.5 grams
Number of subjects: 12
Study 23706063 — intervention group
Group type: EXPERIMENTAL
Intervention: Triticum monococcum (Tm)
Number of subjects: 12
Study 23706063 — intervention group
Group type: COMPARATOR
Intervention: Rice
Number of subjects: 12
Study 23706063 — intervention group
Group type: COMPARATOR
Intervention: Amygluten
Number of subjects: 12
Study 21516545 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructed emotion regulation (increase and decrease instructions)
Number of subjects: 0
Study 18469350 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (5.2 g daily for 12 weeks)
Number of subjects: 46
Study 18469350 — intervention group
Group type: COMPARATOR
Intervention: Olive oil placebo (for 12 weeks)
Number of subjects: 46
Study 16517955 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral 800 IU vitamin E and 500 mg vitamin C (n = 24)
Number of subjects: 96
Study 16517955 — intervention group
Group type: EXPERIMENTAL
Intervention: B-group vitamins (5 mg folic acid, 5 mg vitamin B(2), 50 mg vitamin B(6), and 0.4 mg of vitamin B(12); n = 24)
Number of subjects: 96
Study 16517955 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vitamins together (n = 24)
Number of subjects: 96
Study 16517955 — intervention group
Group type: COMPARATOR
Intervention: No supplementation (control group; n = 24)
Number of subjects: 96
Study 12706363 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumour excision plus tamoxifen
Number of subjects: 136
Study 12706363 — intervention group
Group type: COMPARATOR
Intervention: Mastectomy
Number of subjects: 136
Study 10921768 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg once daily) with salmeterol placebo
Number of subjects: 1200
Study 10921768 — intervention group
Group type: COMPARATOR
Intervention: Inhaled salmeterol (100 microg daily) with montelukast placebo
Number of subjects: 1200
Study 8725733 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (330 mg/day)
Number of subjects: 115
Study 8725733 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine (200 mg/day)
Number of subjects: 115